<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049903</url>
  </required_header>
  <id_info>
    <org_study_id>MP0310-CP101</org_study_id>
    <secondary_id>2018-004786-13</secondary_id>
    <nct_id>NCT04049903</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety, Blood Levels and Activity of MP0310 (AMG 506) in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A First-In-Human, Single-Arm, Multi-Center, Open-Label, Repeated-Dose, Dose-Escalation Study of MP0310 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molecular Partners AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molecular Partners AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of MP0310, a DARPin® therapeutic candidate for tumor
      targeted activation of T cells, in patients with advanced solid tumors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>From signing of informed consent form (ICF) until 10 weeks following the last dose or start of new anticancer therapy.</time_frame>
    <description>According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>First 21 days of dosing.</time_frame>
    <description>Dose-limiting toxicities will be reviewed as a subset of AEs that occur within the first 21 days of dosing and meet the protocol-specified criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) or a tolerated dose below MTD (if MTD is not reached)</measure>
    <time_frame>From signing of ICF until 10 weeks following the last dose or start of new anticancer therapy.</time_frame>
    <description>Based on occurrence of DLTs within a 3+3 clinical trial design</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended expansion dose (RED)</measure>
    <time_frame>From signing of ICF until 10 weeks following the last dose or start of new anticancer therapy.</time_frame>
    <description>Based on incidence and nature of DLTs, and incidence, nature, and severity of AEs and serious adverse events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration - time profiles</measure>
    <time_frame>24 months</time_frame>
    <description>Including parameters like maximal serum concentration (Cmax), time at Cmax (Tmax), minimal serum concentration (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC)</measure>
    <time_frame>24 months</time_frame>
    <description>Pharmacokinetic (PK) analysis of MP0310</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance (CL)</measure>
    <time_frame>24 months</time_frame>
    <description>PK analysis of MP0310</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd), volume at steady state (Vss)</measure>
    <time_frame>24 months</time_frame>
    <description>PK analysis of MP0310</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>24 months</time_frame>
    <description>PK analysis of MP0310</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio</measure>
    <time_frame>24 months</time_frame>
    <description>PK analysis of MP0310</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug-antibodies</measure>
    <time_frame>24 months</time_frame>
    <description>Serum concentration-time profile of anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>The proportion of participants with confirmed complete response (CR) and partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 months</time_frame>
    <description>Stable disease lasting 4 or more weeks following the initiation of MP0310</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>24 months</time_frame>
    <description>For participants with CR or PR, DOR will be calculated as time from initial response of CR or PR to progressive disease or death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>MP0310 (AMG 506)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment will follow a standard 3 + 3 dose escalation design. Sequential Cohorts of patients will be dosed until the MTD is exceeded, unacceptable toxicity is reached, or until the maximum protocol specified dose is delivered. Up to 12 additional patients in total may be included at selected dose levels (up to 3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP0310 (AMG 506)</intervention_name>
    <description>MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors</description>
    <arm_group_label>MP0310 (AMG 506)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Advanced solid tumor of one of the following types, treated with at least one line of
             systemic therapy, with no available treatment options: Colorectal, Ovarian,
             Endometrial, Gastric, Pancreatic, Anal, Cervical, Squamous cell cancer of the head and
             neck, Mesothelioma, Prostate, Non-small cell lung cancer, Melanoma,
             Urothelial/bladder, Microsatellite instability high tumors of any type, Cutaneous
             squamous cell

          -  ≥18 years of age

          -  Eastern Cooperative Oncology Group performance status (ECOG; PS) ≤1

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
             v1.1 criteria

          -  Mandatory paired (pre- and on-treatment) biopsies

          -  Adequate organ function as defined in the protocol

          -  A woman of childbearing potential (WOCBP) should only be included after a confirmed
             menstrual period and a negative serum pregnancy test at Screening.

          -  Female participant is eligible to participate if she is not pregnant, not
             breastfeeding, and at least one of the following conditions applies:

               -  Not a woman of child bearing potential (WOCBP) as defined in the protocol

               -  A WOCBP who agrees to follow the contraceptive guidance as defined in the
                  protocol

          -  Men who are not surgically sterilized and who are partners of WOCBP must be willing to
             use adequate contraception as detailed in the protocol

        Exclusion Criteria

          -  Autoimmune diseases, except auto-immune endocrinopathies that are stable with hormone
             replacement therapy

          -  Inflammatory diseases such as arthritis, colitis, liver fibrosis, cirrhosis,
             interstitial fibrosis, or chronic obstructive pulmonary disease (COPD)

          -  Bisphosphonate therapy for symptomatic hypercalcemia

          -  Use of an investigational agent within the past 4 weeks before first MP0310
             administration in this study

          -  Any anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy,
             within 3 weeks prior to first MP0310 administration; however, the following are
             allowed:

               -  Hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists or
                  antagonists for prostate cancer

               -  Hormone-replacement therapy or oral contraceptives

               -  Palliative radiotherapy for bone metastases 2 weeks prior to first MP0310
                  administration

          -  Corticosteroid use exceeding 10 mg/day prednisone or equivalent

          -  Left ventricular ejection fraction of &lt;50%

          -  Any history or evidence of clinically significant cardiovascular disease as defined in
             the protocol

          -  Severe dyspnea, pulmonary dysfunction, or need for continuous supportive oxygen
             inhalation

          -  Arterial thromboembolic event, stroke, or transient ischemia attack within the past 12
             months

          -  Known central nervous system (CNS) metastasis that are either untreated or are treated
             but are associated with clinical symptoms (e.g., headache, convulsions). Participants
             with CNS metastasis that have been treated with radiotherapy and/or surgery are
             eligible if they are clinically without symptoms for at least 6 weeks; if under
             treatment with corticosteroids (not exceeding 10 mg/day prednisone or equivalent)
             and/or anticonvulsive agents patients must be on a stable dose for at least two weeks.

          -  Any active uncontrolled bleeding, or a bleeding diathesis

          -  Patients with a known positivity for human immunodeficiency virus (HIV)

          -  Patients with active hepatitis B (chronic or acute; HBV)

          -  Patients with active hepatitis C (HCV) infection

          -  Serious or non-healing wound, skin ulcer, or non-healing bone fracture

          -  Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the
             past 6 months

          -  Albumin &lt;2.8 g/dL or &lt;28 g/L, and without albumin transfusion for ≥7 days prior to
             screening

          -  Any live virus vaccine within 30 days prior to the start of therapy (Note: Inactivated
             seasonal flu vaccine is acceptable)

          -  Has had an allogenic tissue/solid organ transplant

          -  History of another primary malignancy except for:

               -  Malignancy treated with curative intent and with no known active disease ≥2 years
                  before the first dose of investigational product and of relatively low potential
                  risk for recurrence

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease

               -  Adequately treated carcinoma in situ without evidence of disease

               -  Incidental histologic findings of prostate cancer that, in the opinion of the
                  Investigator, is not deemed to require active therapy

          -  Male or female participants of reproductive potential who are not willing to employ
             adequate contraception from screening to 3 months after the last MP0310 administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Director, MPAG</last_name>
    <phone>+41 44 755 7700</phone>
    <email>info@molecularpartners.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud; Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O)</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Insitut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

